iSpecimen (iSpecimen) 3-Year EPS without NRI Growth Rate : -5.10% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is iSpecimen 3-Year EPS without NRI Growth Rate?

iSpecimen's EPS without NRI for the three months ended in Dec. 2023 was $-0.34.

During the past 3 years, the average EPS without NRI Growth Rate was -5.10% per year. During the past 5 years, the average EPS without NRI Growth Rate was -7.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 6 years, the highest 3-Year average EPS without NRI Growth Rate of iSpecimen was -5.10% per year. The lowest was -21.70% per year. And the median was -12.70% per year.

Competitive Comparison of iSpecimen's 3-Year EPS without NRI Growth Rate

For the Diagnostics & Research subindustry, iSpecimen's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iSpecimen's 3-Year EPS without NRI Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, iSpecimen's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where iSpecimen's 3-Year EPS without NRI Growth Rate falls into.

iSpecimen 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

iSpecimen (NAS:ISPC) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

iSpecimen 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of iSpecimen's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

iSpecimen (iSpecimen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » iSpecimen Inc (NAS:ISPC) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

450 Bedford Street, Lexington, MA, USA, 02420

Website

https://www.ispecimen.com

iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.

Executives

Benjamin Bielak	officer: Chief Information Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Tracy Curley	officer: Chief Financial Officer	450 BEDFORD STREET, LEXINGTON MA 02420
Joseph J. Basile	director	450 BEDFORD STREET, LEXINGTON MA 02420
Andrew L. Ross	director, 10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Gullans Steven R. Ph.d.	director	C/O EXCEL VENTURE MANAGEMENT, LLC, 800 BOYLSTON ST., STE 2825, BOSTON MA 02199
John L Brooks	director	100 LOWDER BROOK DRIVE SUITE 2500, WESTWOOD MA 02090
Obf Investments, Llc	10 percent owner	450 BEDFORD STREET, LEXINGTON MA 02420
Margaret H. Lawrence	director	450 BEDFORD STREET, LEXINGTON MA 02420
George H. Scholl	director	450 BEDFORD STREET, LEXINGTON MA 02420
Christopher Ianelli	director, officer: CEO, President	450 BEDFORD STREET, LEXINGTON MA 02420
Jill Mullan	director, officer: COO, Secretary, Treasurer	450 BEDFORD STREET, LEXINGTON MA 02420